🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT04631133
Recruiting Observational

LISA Post Market Clinical Follow-Up Study: Documentation of Clinical Outcomes After Surgery With LISA Implant

NCT04631133 · tracked via the Priya Life Science Germany tracker
Sponsor
BACKBONE
Phase
Observational
Started
2019-04-17
Last updated
2022-07-21

Condition(s) studied

Chronic Low-back PainHerniated DiscDegenerative Disc DiseaseLumbar Canal Stenosis

Investigational drug(s) / intervention(s)

Lumbar Implant for Stiffness Augmentation (LISA)

Lumbar Implant for Stiffness Augmentation (LISA): The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).

Study summary

The study is a post-market surveillance study of the Lumbar Implant for Stiffness Augmentation (LISA), a medical device, which is used to treat low-back pain that accompanies degenerative lesions of grades II, III, and IV (Pfirrmann MRI classification). "Post-market" means the device (i.e. the LISA implant) being used in this study has already obtained CE certification and is commercially available for use in the European market.

The LISA device consists of 3 components: A PEEK interspinous spacer, a polyester band, and a titanium blocker. The spacer is positioned between two adjacent spinous processes, the band is belted around the spinous processes and through the spacer, and the blocker is used to lock the band inside the spacer.

Medical Device manufacturers conduct "post-market" clinical studies in order to continuously evaluate the product scientifically and to comply with legal and ethical obligations. With these studies, the long-term safety as well as performance of their medical devices are assessed.

This study, which is initiated and sponsored by BACKBONE (LISA designer, developer, manufacturer and marketer), aims to evaluate the long-term safety and performance of the LISA implant for the treatment of lumbar degenerative disease and to evaluate the treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Skeletally mature patients Patient ≥18 years of age * Patients with low-back pain caused by degenerative lesions of grade II, III and IV (Pfirrmann MRI classification) * Failed conservative treatment for low back pain conducted for at least 6 months Exclusion Criteria: * Stage V degenerative disk lesions in Pfirrmann's MRI classification * Spondylolisthesis * Osteoporosis * Non-specific back pain * Modic 2 and Modic 3 changes * L5/S1 segments affected * Local or general infections that may compromise the surgical goals * Major local inflammatory phenomena * Pregnant and lactating Women * Immunosuppressive diseases * Bone immaturity * Severe mental illnesses * Bone metabolism diseases that may compromise the mechanical support expected from this type of implant * Patient with worker's compensation, under litigation or on disability benefits * Excessive physical activities * Patients deprived of their liberty in accordance with respective national regulations * Protected patients or patients not in a position to declare his or her consent in accordance with respective national regulations

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Elective Surgery Center, Silkeborg Regional Hospital Silkeborg Denmark Recruiting
Pellegrin University Hospital Center Bordeaux France Recruiting
Saint-Charles Clinic Lyon France Recruiting
Pitié-Salpêtrière University Hospital Center Paris France Recruiting
Asklepios Stadtklinik, Bad Wildungen Bad Wildungen Germany Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04631133 on ClinicalTrials.gov ↗ ← All trials in Germany